DOI QR코드

DOI QR Code

Bioequivalence of Sinil Atenolol Tablets to Tenormin Tablets (Atenolol 50 mg)

테놀민 정(아테놀올 50 mg)에 대한 신일아테놀올 정의 생물학적 동등성

  • Published : 2003.03.20

Abstract

This study was conducted to compare the bioavailability of a generic product of Sinil Atenolol Tablets (Sinil Pharmaceutical Co., Ltd., Korea) with the innovator product, $Tenormin^{\circledR}$ Tablets in 20 healthy Korean volunteers. The volunteers received a single 50 mg dose of each atenolol formulation according to a randomized, two-way crossover design. Plasma samples were obtained over a 24-hour interval, and atenolol concentrations were determined by HPLC with a fluorescence detector. From the plasma atenolol concentration vs time curves, the following parameters were compared: area under the plasma concentration-time curve (AUC), peak plasma concentration $(C_{max})$, time to reach peak plasma concentration $(T_{max})$, and terminal first order elimination half-life $(t_{1/2})$. No statistically significant difference was obtained between the $T_{max}$ values, and the logarithmic transformed AUC and $C_{max}$ values of the two products. The 90% confidence for the ratio of the logarithmically transformed AUC and $C_{max}$ values of Sinil Atenolol Tablets over those of $Tenormin^{\circledR}$ Tablets were calculated to be between 0.99 and 1.07, and 1.04 and 1.16, respectively; both were within the bioequivalence limit of 0.80-1.25. The mean of $T_{max}$ in $Tenormin^{\circledR}$ Tablet group was 3.68 hour, and that in Sinil Atenolol Tablet group was 3.65 hour. The values of $t_{1/2}$ between the two products were found comparable, and the mean $t_{1/2}$ values of $Tenormin^{\circledR}$ Tablets and Sinil Atenolol Tablets were 5.9 and 6.0 hour, respectively. Based on these results, it was concluded that Sinil Atenolol Tablets were comparable to $Tenormin^{\circledR}$ Tablets in both the rate and extent of absorption, indicating that Sinil Atenolol Tablets were bioequivalent to the reference product, $Tenormin^{\circledR}$ Tablets

Keywords

References

  1. A.M. Barrett, J. Carter, J.D. Fitzgerald, R. Hull and D.Count, A new type of cardioselective adrenoceptive blocking drug, Br. J. Pharmacol, 48, 340 (1973)
  2. J.D. Harry, M.F. Knapp and R.J. Linden, Proceedings: Antagonism by ICI 66082 of the effects of electrical stimulation on the right ansa subclavia of the dog, Br. J.Pharmacol., 51, 169 (1974) https://doi.org/10.1111/j.1476-5381.1974.tb09644.x
  3. W.H. Frishman, Atenolol and timolol, two new systemic $\hat {a}$-adrenoceptor antagonists, N. Engl J. Med., 306, 1424-1462 (1982) https://doi.org/10.1056/NEJM198206103062315
  4. R.C. Heel, R.N. Brogden, T.M. Speight and G.S. Avery,Atenolol: a review of its pharmacological properties and therapeutic effcacy in angina pectoris and hypertension, Drugs, 17, 425-460 (1979) https://doi.org/10.2165/00003495-197917060-00001
  5. 식품의약품안전청 고시 제 2001-57호, 생물학적 동등성 시험기준 (2001. 9. 5)
  6. K. Stoschitzky, G. Egginger, G. Zemig, W. Klein and W.Lindner, Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, Pharmacokinetic and radioligand binding studies, Chirality, 5, 15-19 (1993) https://doi.org/10.1002/chir.530050104
  7. M.L. Martins, M.A. Pierossi, L.A. Moraes, W. Ribeiro, E.Abbib Jr., G.B. Mendes, A. Poli, G. De Nucci and M.N.Muscara, Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration, Int. J. Clin. Pharmacol Ther., 35, 324-328 (1997)
  8. K.K. Peh, K.H. Yuen, J.W. Wong and W.T. Toh,Comparative bioavailability study of two atenolol table tpreparations, Drug Dev. Ind. Pharm., 25, 357-360 (1999) https://doi.org/10.1081/DDC-100102182
  9. H. Winkler, W. Ried and B. Lemmer, High-perfomance liquid chromatographic method for the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue, J. Chromatogr., 228, 223-234 (1982) https://doi.org/10.1016/S0378-4347(00)80435-1